AF
RVNC

Amalgamated Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History

Amalgamated Financial’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$223K Buy
+11,428
New +$173K ﹤0.01% 1861

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Amalgamated Financial's RVNC Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Revance Therapeutics, Inc. (RVNC) in Q1 2022: 11,428 shares worth $223K. The stake represents ﹤0.01% of the portfolio and ranks #1861 among its holdings.

156 funds tracked by Wall St. Rank hold RVNC as of Q1 2022.

  • Amalgamated Financial held 11,428 shares of Revance Therapeutics, Inc. worth $223K as of Q1 2022.
  • Revance Therapeutics, Inc. was a new Amalgamated Financial position in Q1 2022.
  • Revance Therapeutics, Inc. made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1861 holding.
  • 156 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.